Alcohol and Alcoholism Vol. 35, No. 6, pp. 537-547, 2000
© 2000 Medical Council on Alcoholism
Invited Review
PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH
Alcohol Research Center, Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030, USA
Received 8 December 1999; first review notified 11 June 2000; )
ABSTRACT
During the past decade, renewed interest in medications to prevent relapse in alcoholics has yielded a number of promising candidates. Although two of these medications, naltrexone and acamprosate, are currently in clinical use in a number of countries, overall, their effectiveness appears to be limited. Disulfiram, the deterrent medication that was approved 50 years ago for the treatment of alcoholism, has not consistently been shown to be efficacious. However, since inadequate dosing and other modifiable factors may limit its deterrent effects, the identification of a more potent metabolite of disulfiram appears to warrant further evaluation. Studies of serotonergic agonists for treatment of alcoholism have also yielded inconsistent results. There is evidence, however, that subgroups of alcoholics may respond well to such medications, suggesting that treatment matching may enhance their efficacy. In addition, nalmefene, a compound with effects similar to naltrexone, as well as a sustained release formulation of naltrexone, may enhance the beneficial effects of opioid antagonist therapy. Despite these developments, much remains to be learned about the pharmacotherapy of alcoholism. The ongoing development and evaluation of novel medications should be given a high priority. However, such basic issues as the optimal dosing strategy and duration of treatment for existing therapies are not known. Similarly, combination therapy, involving either multiple medications or the combination of medication with specific psychotherapies, has not been well studied. The utility of specific pharmacotherapies in women, different ethnic/racial groups, adolescent and geriatric patients, and individuals with co-morbid alcohol and drug use disorders (including nicotine dependence) is also largely unknown, as is the appropriateness of medication therapy for treatment of early problem drinkers. The ultimate aim of these efforts is the development of algorithms for the pharmacological treatment of heavy drinking, which incorporate the characteristics of the patient and of pharmacological and psychosocial treatments with demonstrated efficacy. Although a general framework for such an effort currently exists, much detail is needed before it will be of widespread clinical value.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Agabio, P. Marras, G. L. Gessa, and B. Carpiniello Alcohol use disorders, and at-risk drinking in patients affected by a mood disorder, in Cagliari, Italy: sensitivity and specificity of different questionnaires Alcohol Alcohol., November 1, 2007; 42(6): 575 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Lingford-Hughes, S. Welch, and D. J. Nutt Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, September 1, 2004; 18(3): 293 - 335. [PDF]
|
|
|
|
|
|
I. Okulicz-Kozaryn, P. Mikolajczak, E. Kaminska, I. Kaminska, M. Szulc, and T. Bobkiewicz-Kozlowska EFFECT OF NALTREXONE ADMINISTRATION ON SHORT-TERM MEMORY IN CHRONICALLY ETHANOL-TREATED OUTBRED RATS Alcohol Alcohol., January 1, 2004; 39(1): 14 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gual, M. Balcells, M. Torres, M. Madrigal, T. Diez, and L. Serrano SERTRALINE FOR THE PREVENTION OF RELAPSE IN DETOXICATED ALCOHOL DEPENDENT PATIENTS WITH A COMORBID DEPRESSIVE DISORDER: A RANDOMIZED CONTROLLED TRIAL Alcohol Alcohol., November 1, 2003; 38(6): 619 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Niederhofer, W. Staffen, and A. Mair COMPARISON OF CYANAMIDE AND PLACEBO IN THE TREATMENT OF ALCOHOL DEPENDENCE OF ADOLESCENTS Alcohol Alcohol., January 1, 2003; 38(1): 50 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken, R. Holzbach, P. Kampf, R. Stracke, M. Baehr, D. Naber, et al. Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study Arch Gen Psychiatry, January 1, 2003; 60(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Addolorato, F. Caputo, E. Capristo, M. Domenicali, M. Bernardi, L. Janiri, R. Agabio, G. Colombo, G. L. Gessa, and G. Gasbarrini BACLOFEN EFFICACY IN REDUCING ALCOHOL CRAVING AND INTAKE: A PRELIMINARY DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY Alcohol Alcohol., September 1, 2002; 37(5): 504 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Olive, H. N. Koenig, M. A. Nannini, and C. W. Hodge Stimulation of Endorphin Neurotransmission in the Nucleus Accumbens by Ethanol, Cocaine, and Amphetamine J. Neurosci., December 1, 2001; 21(23): RC184 - RC184. [Abstract] [Full Text] [PDF]
|
|